GGrantIndex
Sort

48,018 grants matching immunotherapy

First-in-human study of a potent anti-HBsAg neutralizing antibody

$864,658
Marina Caskey · Rockefeller University · U01 · FY2023 · AI

Integrated Multi-omics of Melioidosis

$864,642
Timothy Eoin West · University Of Washington · R01 · FY2020 · AI

Multidisciplinary Collaborative Research in NIDDK Program Area Diseases

$864,620
James Balow · National Institute Of Diabetes And Digestive And Kidney Diseases · ZID · FY2012 · DK

Preclinical Development of a Novel and Powerful Immunotherapeutic

$864,478
Susan Dana Jones · Immurx Llc · R44 · FY2013 · AI

Innovation of Biobanking for Cellular Adoptive Immunotherapies Based on a First-in-Class Biocompatible Cryopreservation Technology for T and NK Cells and Their CAR-Engineered Products

$864,173
Xu Han · Cryocrate, Llc · R44 · FY2023 · CA

Programming T Cell Fates for Therapeutic Use

$864,150
Luca Gattinoni · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

COVID-19 vaccine development

$863,806
George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy

$863,755
Jyothi Rengarajan · Emory University · R01 · FY2024 · AI

Clinical trials employing cancer vaccine combination therapies

$863,733
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines

$863,733
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

NIH Chronic GVHD Study Group

$863,692
Steven Pavletic · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Mesothelin-targeted immunotoxins in Pancreatic Cancer

$863,617
Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Biostatistics Shared Resources Core

$863,560
Motomi Mori · St. Jude Children'S Research Hospital · P30 · FY2020 · CA

Biostatistics Shared Resources Core

$863,560
Motomi Mori · St. Jude Children'S Research Hospital · P30 · FY2023 · CA

Biostatistics Shared Resources Core

$863,560
Motomi Mori · St. Jude Children'S Research Hospital · P30 · FY2022 · CA

Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host

$863,419
Ronald Levy · Stanford University · R35 · FY2020 · CA

Antibody Based Therapeuticcs for Chikungunya Virus

$863,223
Michael S. Diamond · Washington University · R01 · FY2011 · AI

Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea

$862,755
Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · AI

BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma

$862,729
Damian J. Green · Fred Hutchinson Cancer Center · P01 · FY2022 · CA

Rapid disease progression and viral reservoir formation in SIV-infected infant macaques

$862,669
Donald L Sodora · Seattle Children'S Hospital · R01 · FY2024 · AI

Southern Nevada Cancer Research Foundation--CCOP

$862,500
Southern Nevada Cancer Research Fdn · U10 · FY2005 · CA

Immune Mechanisms, Genetic and Environmental Factors Influencing Outcomes

$862,445
Scott H Sicherer · Icahn School Of Medicine At Mount Sinai · U19 · FY2010 · AI

A new humanized mouse model to study HBV gene editing

$862,440
Keith R Jerome · Fred Hutchinson Cancer Center · R01 · FY2024 · AI

Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational Approach

$862,207
R. Brad Jones · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · AI

BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma

$861,992
Damian J. Green · Fred Hutchinson Cancer Research Center · P01 · FY2020 · CA